IRIS
D'ANGELO, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.351
EU - Europa 3.227
AS - Asia 2.339
AF - Africa 10
SA - Sud America 4
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.935
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.316
CN - Cina 2.206
IE - Irlanda 1.067
UA - Ucraina 635
FI - Finlandia 485
DE - Germania 395
SE - Svezia 221
IT - Italia 166
GB - Regno Unito 150
SG - Singapore 79
FR - Francia 40
CA - Canada 33
IN - India 28
BE - Belgio 20
JP - Giappone 13
NL - Olanda 13
CZ - Repubblica Ceca 9
RU - Federazione Russa 9
MU - Mauritius 8
TR - Turchia 6
MK - Macedonia 5
AT - Austria 2
AU - Australia 2
CO - Colombia 2
EG - Egitto 2
NO - Norvegia 2
PL - Polonia 2
BD - Bangladesh 1
BG - Bulgaria 1
BR - Brasile 1
CH - Svizzera 1
CR - Costa Rica 1
EU - Europa 1
GR - Grecia 1
ID - Indonesia 1
IQ - Iraq 1
IR - Iran 1
KH - Cambogia 1
KR - Corea 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
Totale 9.935
Salva come PNG Salva come JPEG
Città #
Dublin 1.067
Chandler 894
Jacksonville 848
Nanjing 653
Boardman 328
Nanchang 287
Ashburn 258
Shenyang 198
Princeton 194
Lawrence 190
Medford 186
Hebei 180
Wilmington 172
Changsha 162
Jiaxing 162
Beijing 155
Helsinki 148
Hangzhou 108
Tianjin 97
Ann Arbor 90
Shanghai 70
Woodbridge 53
Singapore 52
Cambridge 51
Seattle 33
Milan 31
Piscataway 31
Toronto 30
Pavia 28
Fairfield 26
New York 26
Norwalk 24
Des Moines 22
Jinan 21
Pune 21
Kunming 19
Los Angeles 19
Brussels 18
Verona 17
Taizhou 12
Ningbo 11
Orange 11
Tokyo 11
Washington 11
Guangzhou 9
Brno 8
West Jordan 8
Berlin 7
Eindhoven 7
Fuzhou 7
Dallas 6
Dearborn 6
Houston 5
Lanzhou 5
Redwood City 5
Rome 5
San Francisco 5
Zhengzhou 5
Auburn Hills 4
Collegno 4
Genoa 4
Isernia 4
Paris 4
Portland 4
Skopje 4
Tappahannock 4
Catania 3
Haikou 3
Hanover 3
Hefei 3
London 3
North Charleston 3
Parma 3
Varanasi 3
Bareggio 2
Bogotá 2
Bruino 2
Changchun 2
Falkenstein 2
Falls Church 2
Frankfurt am Main 2
Grandate 2
Gunzenhausen 2
Jinhua 2
Kochi 2
Magnago 2
Molfetta 2
Moscow 2
Oslo 2
Phoenix 2
Potomac 2
Prineville 2
Sacramento 2
Salerno 2
Almere Stad 1
Amsterdam 1
Atella 1
Atlanta 1
Bitola 1
Borås 1
Totale 7.215
Salva come PNG Salva come JPEG
Nome #
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial 148
Plasma eotaxin concentrations are associated with angiographic severity of coronary artery disease 93
Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. 90
Relationship between plasma levels of soluble receptor for advanced glycation end products (sRAGE) and coronary artery disease 87
RAGE : a central player in nondiabetic vascular disease 81
The Apolipoprotein(a) Component of Lipoprotein(a) Mediates Binding to Laminin: Contribution to Selective Retention of Lipoprotein(a) in Atherosclerotic Lesions 81
Relationship between apolipoprotein(a) size polimorphism and coronary heart disease in overweight subjects 80
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men 78
ATPases of synaptic plasma membranes and vesicles from rat cerebral cortex during aging and hypoxia 77
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 76
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension 75
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 75
Absence of Kir6.1/KCNJ8 mutations in Italian patients with abnormal coronary vasomotion 75
Confronto tra nateglinide più metformina rispetto a glibenclamide più metformina sul metabolismo glucidico nei pazienti diabetici di tipo 2: studio ad 1 anno 73
The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin:contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. 72
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 72
The regulatory chemokine eotaxin-3 is a novel predictor of cardiovascular outcome in patients with coronary artery disease 71
Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT 71
CORRELAZIONE TRA I LIVELLI PLASMATICI DI NEUROTROFINE, SINTOMATOLOGIA DEPRESSIVA E ATEROSCLEROSI CORONARICA 71
Galectin-3 plasma levels andcoronary artery disease: a new possible biomarker of acute coronary syndrome. 70
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome 69
Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study 69
Twenty-four-hour blood pressure profile, orthostatic hypotension, and cardiac dysautonomia in elderly type 2 diabetic hypertensive patients 67
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 66
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 66
Effects of berberine on lipid profile in subjects with low cardiovascular risk 66
Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. 66
Effect of Diazepam on 24-Hour Blood Pressure and Heart Rate in Healthy Young Volunteers 65
Biomarcatori infiammatori e neuro-ormonali nella fibrillazione atriale persistente; ruolo prognostico della concentrazione plasmatica di apelina 64
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 64
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load 64
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans 62
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 62
Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. 62
Effect of in vivo administration of naloxone on ATP-ase's enzyme systems of synaptic plasma membranes from rat cerebral cortex 62
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial 62
Circulating levels of soluble receptor for advanced glycation end products in neurodegenerative and vascular dementia 61
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride 61
Acarbose compared to placebo on insulin resistance biomarkers in a double-blind, placebo-controlled trial 61
Metalloproteasi-2, metalloproteasi-9 ed inibitore tissutale delle metalloproteasi-1 in pazienti ipertesi 61
Prevalence of erectile dysfunction in males affected by type 2 diabetes and the impact of hyperinsulinemia 61
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 61
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease 61
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin 60
Differenti effetti di candesartan e olmesartan sui parametri di attività del tessuto adiposo in pazienti diabetici di tipo 2 ipertesi 60
Prevalence and associations of erectile dysfunction in a sample of italian males with type 2 diabetes. 60
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolismo glucidico e lipidico nei soggetti obesi diabetici di tipo 2 60
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients 59
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients 59
Effetti metabolici di telmisartan e di irbesartan in pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone: un trial clinico randomizzato a doppio cieco 59
Telmisartan ed irbesartan nei diabetii di tipo 2 trattati con rosiglitazone: effetti sull'insulino-resistenza, la leptine e il TNF-alfa 59
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients 59
Lipoprotein (a) Particles Characterization by Dynamic Light Scattering 59
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients 58
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 58
Correlazione tra livelli plasmatici di galactina e aterosclerosi coronarica: nuovo marcatore di instabilità clinica? 58
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 58
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin 58
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 57
Matrix metalloproteinase-2 and – 9 levels in obese patients 57
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients 57
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 57
Effetti di pioglitazone e rosiglitazone nei pazienti con diabete di tipo 2 e sindrome metabolica trattati con metformina 57
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus 57
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 57
MMP-2, -9 and TIMP-1 in patients with hypertension before and after doxazosin therapy 57
Candesartan effect on inflammation in hypertension 56
La terapia con rosiglitazone migliora i parametri di insulino-resisitenza nei pazienti diabetici in sovrappeso ed obesi intolleranti alla metformina 56
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 56
Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk. 56
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 56
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial 56
Low plasma apelin levels predict arrhythmia recurrence in patients with persistent atrial fibrillation 56
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 56
Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk 55
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 55
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 55
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 55
Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease 55
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study 55
Effect of Evening Bromazepam Administration on Blood Pressure and Heart Rate in Mild Hypertensive Patients 55
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy 54
Le metalloproteasi-2, -9 in differenti gruppi con e senza diabete 54
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 54
Effetti di sitagliptin o metformina associati a pioglitazone in pazienti diabetici scarsamente controllati 54
Effects of sibutramine plus L-carnitine compared to sibutramine or placebo on inflammatory parameters 54
Effetti di una combinazione di un estratto di berberis aristata/silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti dislipidemici 54
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects 54
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients 53
Effetti di un anno di trattamento con orlistat+L-carnitina paragonato a orlistat o placebo sui parametri di insulino-resistenza nei pazienti diabetici 53
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 53
Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance 53
Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease 53
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study 52
Effetti di un anno di trattamento con vildagliptin associato a pioglitazone o glimepiride in pazienti diabetici scarsamente controllati 52
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients 52
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 52
The apolipoprotein(a) size polymorphism is assocated with Alzheimer's disease and vascular dementia 51
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial 51
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 51
Totale 6.256
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.952
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.952
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020746 0 0 0 118 2 140 36 128 11 216 90 5
2020/20211.190 140 110 37 117 2 160 9 187 43 186 157 42
2021/2022740 12 4 30 5 6 10 5 46 44 15 119 444
2022/20232.856 286 200 20 189 282 283 2 163 1.253 35 90 53
2023/2024972 110 179 28 58 88 226 5 100 9 39 61 69
2024/2025355 29 237 88 1 0 0 0 0 0 0 0 0
Totale 10.158